{"id":"NCT04320615","sponsor":"Hoffmann-La Roche","briefTitle":"A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-04-03","primaryCompletion":"2020-06-24","completion":"2020-07-28","firstPosted":"2020-03-25","resultsPosted":"2021-06-30","lastUpdate":"2021-06-30"},"enrollment":452,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["COVID-19 Pneumonia"],"interventions":[{"type":"DRUG","name":"Tocilizumab (TCZ)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tocilizumab (TCZ) Arm","type":"EXPERIMENTAL"},{"label":"Placebo Arm","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab (TCZ) compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with severe COVID-19 pneumonia.","primaryOutcome":{"measure":"Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 28 (Week 4)","timeFrame":"Day 28","effectByArm":[{"arm":"Tocilizumab (TCZ) mITT Arm","deltaMin":56.5,"sd":null},{"arm":"Placebo Modified Intent-to-Treat (mITT) Arm","deltaMin":49.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.3600"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":12},"locations":{"siteCount":62,"countries":["United States","Canada","Denmark","France","Germany","Italy","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":["35475258","34612846","33631066"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":64,"n":143},"commonTop":["Anaemia","Urinary tract infection","Constipation","Hypertension","Diarrhoea"]}}